Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open ‐Label Transition From Reference Infliximab to Biosimilar Infliximab

ConclusionIn our cohort, one‐fourth of patients discontinued CT‐P13 during 6 months of follow‐up, mainly due to an increase in the subjective features of the tender joint count and the patient's global assessment of disease activity and/or subjective AEs, possibly explained by nocebo effects and/or incorrect causal attribution effects.

Source: Arthritis and Rheumatism - December 7, 2017 Category: Rheumatology Authors: Lieke Tweehuysen, Bart J. F. Bemt, Iris L. Ingen, Alphons J. L. Jong, Willemijn H. Laan, Frank H. J. Hoogen, Alfons A. Broeder Tags: Original Article Source Type: research